Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing Pharmaceutical Business ReviewThe funds will be used for AsymBio's principal business operations and drive further expansion of its manufacturing capacity.Read full story pharminent August 5, 2026 (Last updated: August 5, 2026) Pharmaceutical Business Review The funds will be used for AsymBio’s principal business operations and drive further expansion of its manufacturing capacity. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer Axes Ex-Metsera Obesity Asset and GIPR Prospect in Quarterly Pipeline ClearoutNext: Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts Related Stories Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026 Manufacturing GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy pharminent July 29, 2026 Manufacturing GSK to quit Stevenage for new R&D site in Cambridge pharminent July 28, 2026
